Anti-NMDA receptor encephalitis classification: Difference between revisions
| Line 52: | Line 52: | ||
[[Category:Rheumatology]] | [[Category:Rheumatology]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
<ref name="pmid24360484">{{cite journal| author=Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F | display-authors=etal| title=Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. | journal=Lancet Neurol | year= 2014 | volume= 13 | issue= 2 | pages= 167-77 | pmid=24360484 | doi=10.1016/S1474-4422(13)70282-5 | pmc=4006368 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24360484 }} </ref> | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 05:49, 13 May 2023
|
Anti-NMDA receptor encephalitis Microchapters |
|
Differentiating Anti-NMDA receptor encephalitis from Other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Anti-NMDA receptor encephalitis classification On the Web |
|
American Roentgen Ray Society Images of Anti-NMDA receptor encephalitis classification |
|
Directions to Hospitals Treating Anti-NMDA receptor encephalitis |
|
Risk calculators and risk factors for Anti-NMDA receptor encephalitis classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; AE Dheeraj Makkar, M.D.[2]
Overview
Anti-NMDA encephalitis can be categorized into three distinct subtypes based on the timing of onset and duration of the illness.
Classification
Anti NMDA Encephalitis may be classified into three subtypes, depending on the timing of presentation and duration.
| Subtype | Symptoms | Duration |
|---|---|---|
| Class 1 | Primarily catatonic or stuporous state | Less than 60 days |
| Class 2 | Primarily psychotic state | More than 60 days |
| Class 3 | Primarily catatonic or stuporous state | More than 60 days |
References
- ↑ Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F; et al. (2014). "Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study". Lancet Neurol. 13 (2): 167–77. doi:10.1016/S1474-4422(13)70282-5. PMC 4006368. PMID 24360484.